Concizumab is a medicine used to prevent bleeding in people with hemophilia A or B. It works by blocking a natural brake on blood clotting, so the blood can clot better. It is given as a daily shot under the skin with a pen.
Every report comes from a Lived member, sent anonymously.
Have you tried Alhemo (Concizumab) for Hemophilia A?
Concizumab, sold as Alhemo, is a prescription medicine taken every day to prevent bleeding episodes in people with hemophilia A or hemophilia B. It is approved for adults and children 12 and older, including people who have developed inhibitors. Inhibitors are antibodies that attack replacement clotting factor and make standard factor treatment far less effective. Alhemo is preventive treatment, often called prophylaxis. It lowers how often bleeds happen; it is not used to treat a bleed that has already started. It is one of several non-factor options that are injected under the skin rather than into a vein. Another is emicizumab (Hemlibra), which is approved only for hemophilia A. Standard factor replacement, given into a vein, also remains an option for many people.
Hemophilia A and B are inherited conditions in which the blood lacks enough of one clotting protein (factor VIII or factor IX), so clots form slowly and bleeds last longer. The body also has natural brakes on clotting. One of them, tissue factor pathway inhibitor (TFPI), damps down the first steps of clot formation. Concizumab is a monoclonal antibody, a lab-made protein that attaches to one specific target. It binds TFPI and blocks its braking effect, which lets the body generate more thrombin, the enzyme that turns liquid blood into a clot. Because it works around the missing factor instead of replacing it, inhibitors against factor VIII or IX do not reduce its effect, and it does not cause those inhibitors to form.
Alhemo comes in a prefilled pen and is injected under the skin of the belly or thigh once a day, using a different spot each day. After training, people can inject it themselves or a caregiver can do it. Each pen is for one person only and must never be shared, even with a new needle. Treatment starts with a larger loading dose on the first day, then a daily dose based on body weight. About four weeks in, a blood test measures the level of concizumab in the blood, and the care team uses the result to set the long-term daily dose. The level is rechecked at follow-up visits, and the dose is recalculated if body weight changes. Taking it every day keeps protection steady. A missed dose in the first four weeks should be reported to the care team, since it can affect the dose-setting test. Later on, the label gives specific catch-up rules depending on how many doses were missed, and after a week or more of missed doses the care team may restart with a new loading dose. Ask for these instructions in writing when starting.
The most common side effects are reactions where the injection was given, such as bruising, redness or a small lump, along with headache and hives. The most important serious risk is a blood clot. In clinical trials, about 2 in 100 people had a clot in a vein or artery, all in people with several clot risk factors, which in some cases included heavy use of extra factor or bypassing agents (clotting products used for bleeds when inhibitors are present). Swelling, warmth, pain or redness in an arm or leg should prompt a call to the care team right away, including whether to hold the next dose. Signs that a clot may have reached the lungs or heart (shortness of breath, severe chest pain), the brain (sudden confusion, trouble speaking or moving, numbness of the face), the eye (vision problems or eye pain) or the abdomen or kidneys (sudden pain in the stomach or lower back) need emergency care. Allergic reactions can also happen. Rash, hives or itching should be reported to the care team promptly. Swelling of the lips, tongue or face, wheezing, chest tightness, trouble breathing or swallowing, or feeling faint is a possible severe reaction (anaphylaxis) and needs emergency care.
The key interaction is with the treatments used for breakthrough bleeds. Factor VIII, factor IX and bypassing agents (such as recombinant factor VIIa or activated prothrombin complex concentrate, used when inhibitors are present) can still be given, and Alhemo itself does not need a dose change. But high or repeated doses of these products on top of Alhemo increase the risk of clots, so the lowest approved dose is recommended for mild and moderate bleeds. Agree on a written breakthrough-bleed plan with the hemophilia team before you need it. People with conditions that make clots more likely, such as advanced artery disease, cancer, a serious crush injury or a severe bloodstream infection, need careful assessment. Alhemo raises the result of D-dimer, a blood test often used to look for clots, so anyone evaluating a possible clot should know you take it. Alhemo is usually paused at least four days before major surgery and restarted afterward under the team's direction; minor procedures usually need no change. It should not be used by anyone who has had a serious allergic reaction to it. It may harm a developing baby, and there are no human pregnancy data, so pregnancy plans should be discussed before starting. Anyone who could become pregnant should use highly effective birth control while taking Alhemo and for 7 weeks after the last dose, and should ask which method suits them, since some hormonal methods add to clot risk.
In the main trials, people who had been treating bleeds only as they happened had far fewer treated bleeds on daily Alhemo. Among people with inhibitors, the average fell from about 12 to under 2 bleeds a year; people without inhibitors saw reductions of roughly 80%. These trials compared Alhemo with no preventive treatment, not with factor prophylaxis or Hemlibra, so they do not show which option works best for a given person. The first two months involve a loading dose, the level test and a dose adjustment. After that, life usually settles into a quick daily injection, follow-up visits with level checks and keeping a log of any bleeds. Protection depends on staying on schedule, and stopping or missing many doses can leave a person unprotected, so any decision to stop should be made with the hemophilia team.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Alhemo (Concizumab), what you've noticed, or ask the community a question.